Study assessing cognitive function and physical activity in people with relapsing remitting multiple sclerosis.
Study Type
OBSERVATIONAL
Enrollment
1,085
Patients treated with regular dose subcutaneously administered, according to the label and to clinical routine practice.
Unnamed facility
Multiple Locations, Albania
Unnamed facility
Multiple Locations, Algeria
Unnamed facility
Multiple Locations, Argentina
Cognitive performance as measured by SDMT (Symbol Digit Modalities Test)
Time frame: 24 months
Physical activity as measured by the Baecke questionnaire
Time frame: 24 months
Disability as measured by EDSS (Expanded Disability Status Scale)
Time frame: 24 months
Fatigue as measured by FSMC (Fatigue Scale for Motor and Cognitive Functions)
Time frame: 24 months
Depression as measured by the CES-D (Center for Epidemiologic Studies Depression)
Time frame: 24 months
Quality of life as measured by the SF-12 (Mental and physical health-scale measure of quality of life)
Time frame: 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Multiple Locations, Belgium
Unnamed facility
Multiple Locations, Czechia
Unnamed facility
Multiple Locations, Egypt
Unnamed facility
Multiple Locations, France
Unnamed facility
Multiple Locations, Germany
Unnamed facility
Multiple Locations, Greece
Unnamed facility
Multiple Locations, Hungary
...and 7 more locations